Anavex Life Sciences Corp.
http://www.anavex.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Anavex Life Sciences Corp.
Anavex Finds EXCELLENCE Trial To Be Ironically Named
A failure in children with Rett syndrome sees the company’s market value cut by more than a third.
Korea's AriBio Progresses Phase III Program For Oral Alzheimer's Contender
South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.
Does Prothena Have A Best-In-Class Alzheimer’s Drug Waiting In The Wings?
More than 20 years since its forerunner tried to develop the first anti-amyloid drug, Prothena’s CEO tells Scrip about its hopes for producing a best-in-class subcutaneous treatment for Alzheimer’s disease.
Acadia’s Daybue Gets First Approval In Rett Syndrome
Daybue is the first drug approved to treat the rare neurodevelopmental disorder Rett syndrome, despite high clinical trial incidence of diarrhea. Product labeling includes clinician guidance for the side effect.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Anavex Australia Pty Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice